Abu Dhabi Global Healthcare Week Partners with Digital Health New York to Boost Digital Health Ecosystem

By HEOR Staff Writer

October 8, 2023

Unifying Efforts for Digital Health Ecosystem Globally

Abu Dhabi Global Healthcare Week (ADGHW) has partnered with Digital Health New York (DHNY) to enhance the global digital health ecosystem. The Memorandum of Understanding (MoU), signed on October 4, 2023, aims to promote collaboration, innovation, long-term investment, and knowledge exchange in the digital health sector.

The two-year partnership will focus on developing research and innovation in digital health, enhancing credibility in science, and providing access to subject-matter experts through open dialogue.

Tackling Global Healthcare Challenges through Digital Tools

The partnership comes at a time when global healthcare demands require collaboration and access to digital tools. Both ADGHW and DHNY are committed to supporting ongoing research and development initiatives, particularly in genomics, preventative and predictive medicine.

H.E. Dr. Ahmed Alkhazraji, Executive Director, Strategy and Policy at the Department of Health – Abu Dhabi and Bunny Ellerin, Co-Founder & CEO, DHNY, signed the partnership. The collaboration aims to leverage both parties’ rich networks to access long-term investment and forge partnerships in the global digital health arena.

ADGHW and DHNY also emphasise the importance of scientific credibility in the healthcare industry and are joining forces in collaborative research studies and the creation of scientific literature.

Reference url

Recent Posts

Inflation Reduction Act Impact on Clinical Trial Investment Trends

By João L. Carapinha

March 26, 2026

The Inflation Reduction Act Impact is becoming evident in early data on industry-sponsored clinical trials. A recently published JME article examines how the Drug Price Negotiation Program (DPNP) introduced by the IRA may be altering investment incentives for biopharmaceutical innovation.
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles
Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...